LONSURF, ORCANTAS (Servier Laboratories Australia Pty Ltd)
Product name
LONSURF, ORCANTAS
Date registered
Evaluation commenced
Decision date
Approval time
165 working days (255)
Active ingredients
trifluridine; tipiracil hydrochloride
Registration type
EOI
Indication
Gastric cancer
LONSURF, ORCANTAS (film-coated tablets) are now also indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.